Savara Inc (SVRA) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $30.11M; Long-term DebtUSD $30.11M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD $30.07M; Long-term DebtUSD $30.07M; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD $29.91M; Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $0.00; Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD $29.91M; Long-Term Debt, Maturity, Year OneUSD $0.00.
Savara Inc Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Debt Instrument, Fee Amount USD | Long-term Debt, Gross USD | Debt Instrument, Unamortized Discount USD | Long-term Debt and Lease Obligation USD | Long-term Line of Credit USD | Line of Credit Facility, Interest Rate at Period End pure | Line of Credit Facility, Interest Rate During Period pure | Debt Instrument, Interest Rate, Increase (Decrease) pure | Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $30.11M | $30.11M | $0.00 | $11.36M | $14.72M | $6.01M | (m) | $0.00 | $418.00K | $32.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $30.07M | $30.07M | $0.00 | $0.00 | $11.36M | $14.72M | $6.01M | $0.00 | $356.00K | $32.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $29.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | (m) | $29.91M | $0.00 | $0.00 | $11.30M | $14.75M | $6.04M | (m) | $411.00K | $32.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $29.78M | $29.78M | (m) | (m) | $11.30M | $14.75M | $6.04M | $0.00 | $433.00K | $32.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $29.65M | $29.65M | $0.00 | $0.00 | $11.30M | $14.75M | $6.04M | $0.00 | $457.00K | $32.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $29.52M | $29.52M | (m) | (m) | $11.30M | $14.75M | $6.04M | (m) | $481.00K | $32.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $26.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | (m) | $26.62M | (m) | $17.67M | $9.56M | (m) | (m) | (m) | $253.00K | $27.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $24.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $26.55M | $26.55M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $25.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $26.48M | $26.48M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $28.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $26.42M | $26.42M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $30.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $26.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | $26.35M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $33.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | (m) | (m) | $17.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $26.28M | $26.28M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $35.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $26.21M | $26.21M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $38.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $26.14M | $26.14M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $40.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $26.08M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | $26.08M | (m) | (m) | (m) | $17.67M | $9.56M | (m) | (m) | $27.23M | $43.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $26.01M | $26.01M | (m) | (m) | (m) | (m) | $17.67M | (m) | (m) | $27.23M | $45.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $25.94M | $25.94M | (m) | (m) | (m) | (m) | $17.67M | (m) | (m) | $27.23M | $48.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $12.50M | $13.31M | $25.81M | $8.33M | $18.17M | (m) | (m) | (m) | (m) | (m) | $26.50M | $50.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $8.33M | $17.32M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | $25.66M | $8.33M | $18.17M | (m) | (m) | (m) | (m) | (m) | $26.50M | $65.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $4.17M | $21.35M | $25.52M | $8.33M | $18.17M | (m) | (m) | (m) | (m) | (m) | $26.50M | $76.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $25.38M | $25.38M | $8.33M | $18.17M | (m) | (m) | (m) | (m) | (m) | $26.50M | $86.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $25.24M | $25.24M | $8.33M | $18.17M | (m) | (m) | (m) | (m) | (m) | $26.50M | $99.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $25.10M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | $25.10M | (m) | $8.33M | $18.17M | (m) | (m) | (m) | (m) | $26.50M | $113.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.10M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $123.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $133.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $144.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | $2.00M | $12.00M | $12.50M | (m) | (m) | (m) | (m) | $26.50M | $158.00K | (m) | $25.11M | (m) | (m) | (m) | (m) | $340.00K |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $177.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $193.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $212.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | (m) | $2.00M | $12.00M | $12.50M | (m) | (m) | (m) | $26.50M | $235.00K | (m) | $24.53M | (m) | (m) | (m) | (m) | $503.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $190.00K | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $227.00K | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $259.00K | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $5.62M | $7.50M | $2.77M | (m) | (m) | (m) | $15.90M | $293.00K | (m) | $14.78M | (m) | (m) | (m) | $900.00K | $376.00K |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $321.00K | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $347.00K | (m) | (m) | (m) | (m) | (m) | $900.00K | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $57.00K | (m) | (m) | 9.70% | (m) | (m) | $712.50K | (m) |
| 2016-12-31 | (m) | (m) | (m) | $1.78M | $1.78M | $865.00K | (m) | (m) | (m) | (m) | $4.42M | (m) | (m) | $3.83M | 9.45% | (m) | (m) | (m) | $253.00K |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 8.95% | 12 month · -3.25% | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $712.50K | (m) |
| 2015-08-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 8.95% | -3.25% | (m) | (m) |
| 2015-08-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $712.50K | (m) |
| 2015-08-11 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9.20% | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $25.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $27.00K | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |